Lantern Pharma Inc.

NasdaqCM:LTRN Stock Report

Market Cap: US$33.8m

Lantern Pharma Valuation

Is LTRN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LTRN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LTRN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LTRN's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for LTRN?

Key metric: As LTRN is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for LTRN. This is calculated by dividing LTRN's market cap by their current book value.
What is LTRN's PB Ratio?
PB Ratio1.2x
BookUS$26.60m
Market CapUS$33.76m

Price to Book Ratio vs Peers

How does LTRN's PB Ratio compare to its peers?

The above table shows the PB ratio for LTRN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average13.7x
AGE AgeX Therapeutics
5.1xn/aUS$31.5m
ESLA Estrella Immunopharma
49xn/aUS$36.2m
LIAN.Y LianBio
0.2xn/aUS$31.4m
NLTX Neoleukin Therapeutics
0.4xn/aUS$32.8m
LTRN Lantern Pharma
1.2x-3.8%US$33.8m

Price-To-Book vs Peers: LTRN is good value based on its Price-To-Book Ratio (1.2x) compared to the peer average (13.7x).


Price to Book Ratio vs Industry

How does LTRN's PB Ratio compare vs other companies in the US Biotechs Industry?

59 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$594.06m
AMRN Amarin
0.4x-7.7%US$217.60m
IMAB I-Mab
0.4x1.8%US$76.61m
MGX Metagenomi
0.3x-23.2%US$75.22m
LTRN 1.2xIndustry Avg. 1.9xNo. of Companies78PB01.63.24.86.48+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: LTRN is good value based on its Price-To-Book Ratio (1.2x) compared to the US Biotechs industry average (1.9x).


Price to Book Ratio vs Fair Ratio

What is LTRN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LTRN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LTRN's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LTRN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.07
US$20.50
+567.3%
26.8%US$26.00US$15.00n/a2
Nov ’25US$3.31
US$22.00
+564.7%
18.2%US$26.00US$18.00n/a2
Oct ’25US$3.76
US$22.00
+485.1%
18.2%US$26.00US$18.00n/a2
Sep ’25US$4.09
US$22.00
+437.9%
18.2%US$26.00US$18.00n/a2
Aug ’25US$4.06
US$22.00
+441.9%
18.2%US$26.00US$18.00n/a2
Jul ’25US$4.52
US$22.00
+386.7%
18.2%US$26.00US$18.00n/a2
Jun ’25US$6.07
US$22.00
+262.4%
18.2%US$26.00US$18.00n/a2
May ’25US$5.39
US$22.00
+308.2%
18.2%US$26.00US$18.00n/a2
Apr ’25US$9.51
US$20.50
+115.6%
26.8%US$26.00US$15.00n/a2
Mar ’25US$4.15
US$20.50
+394.0%
26.8%US$26.00US$15.00n/a2
Feb ’25US$4.23
US$20.50
+384.6%
26.8%US$26.00US$15.00n/a2
Aug ’24US$4.89
US$18.50
+278.3%
40.5%US$26.00US$11.00US$4.062
Jul ’24US$5.64
US$17.33
+207.3%
36.6%US$26.00US$11.00US$4.523
Jun ’24US$5.31
US$17.33
+226.4%
36.6%US$26.00US$11.00US$6.073
May ’24US$4.96
US$17.33
+249.5%
36.6%US$26.00US$11.00US$5.393
Apr ’24US$4.83
US$17.33
+258.9%
36.6%US$26.00US$11.00US$9.513
Mar ’24US$5.37
US$17.33
+222.8%
36.6%US$26.00US$11.00US$4.153
Feb ’24US$6.08
US$17.33
+185.1%
36.6%US$26.00US$11.00US$4.233
Jan ’24US$6.04
US$18.50
+206.3%
40.5%US$26.00US$11.00US$4.282
Dec ’23US$5.00
US$18.50
+270.0%
40.5%US$26.00US$11.00US$3.742
Nov ’23US$4.41
US$18.50
+319.5%
40.5%US$26.00US$11.00US$2.562

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies